Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
86.38
-2.40 (-2.70%)
At close: Sep 12, 2025, 4:00 PM EDT
86.68
+0.30 (0.35%)
After-hours: Sep 12, 2025, 7:59 PM EDT
Tempus AI Revenue
Tempus AI had revenue of $314.64M in the quarter ending June 30, 2025, with 89.57% growth. This brings the company's revenue in the last twelve months to $951.98M, up 59.84% year-over-year. In the year 2024, Tempus AI had annual revenue of $693.40M with 30.38% growth.
Revenue (ttm)
$951.98M
Revenue Growth
+59.84%
P/S Ratio
15.37
Revenue / Employee
$396,659
Employees
2,400
Market Cap
15.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 693.40M | 161.58M | 30.38% |
| Dec 31, 2023 | 531.82M | 211.15M | 65.85% |
| Dec 31, 2022 | 320.67M | 62.82M | 24.36% |
| Dec 31, 2021 | 257.85M | 69.85M | 37.15% |
| Dec 31, 2020 | 188.00M | 125.95M | 202.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TEM News
- 1 day ago - Tempus AI stock is cheap as Murrey Math Lines points to more gains - Invezz
- 1 day ago - Tempus AI: Is TEM Stock A 10x Growth Story? - Forbes
- 2 days ago - Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging - Benzinga
- 2 days ago - Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device - Business Wire
- 4 days ago - Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer - Business Wire
- 5 days ago - Tempus AI, Inc. (TEM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 5 days ago - After An Odd Start, Tempus AI Is Making A Beeline To The Good End Of The AI Rainbow - Seeking Alpha
- 5 days ago - Tempus AI: Evolving To Data Infrastructure And Monetization Options Platform - Seeking Alpha